Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Decoy Therapeutics’ CEO to Participate in hVIVO Capital Markets Day in London

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors